National Pediatric Myoclonus Center and Neuroimmunology Laboratory, Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL 62794-9643, USA.
J Neuroimmunol. 2012 Feb 29;243(1-2):81-8. doi: 10.1016/j.jneuroim.2011.12.014. Epub 2012 Jan 20.
To study aberrant B cell trafficking into the CSF in opsoclonus-myoclonus syndrome (OMS), chemoattractants CXCL13 and CXCL12, and B cell frequency and CXCR5 expression, were evaluated. CSF CXCL13 concentration and the CSF/serum ratio were higher in untreated OMS than controls, related directly to OMS severity and inversely to OMS duration, and correlated with CSF B cell frequency and oligoclonal bands. CXCL12 showed the opposite pattern. Selective accumulation of CXCR5+ memory B cells in CSF was found. In ACTH-treated OMS, CXCL13, but not CXCL12, was lower. These data implicate the chemokine/chemoreceptor pair CXCL13/CXR5 in B cell recruitment to the CNS in OMS. CXCL13 and CXCL12 may serve as reciprocal biomarkers of disease activity, but CXCL13 also had utility as a treatment biomarker.
为了研究眼震-肌阵挛综合征（OMS）中异常 B 细胞向脑脊液中的迁移，评估了趋化因子 CXCL13 和 CXCL12 以及 B 细胞频率和 CXCR5 表达。未治疗的 OMS 患者的脑脊液 CXCL13 浓度和脑脊液/血清比值高于对照组，与 OMS 严重程度直接相关，与 OMS 持续时间呈负相关，与脑脊液 B 细胞频率和寡克隆带相关。CXCL12 则呈现相反的模式。发现 CXCR5+记忆 B 细胞在脑脊液中选择性聚集。在 ACTH 治疗的 OMS 中，CXCL13 而非 CXCL12 降低。这些数据表明趋化因子/趋化因子对 CXCL13/CXR5 在 OMS 中 B 细胞向中枢神经系统的募集中起作用。CXCL13 和 CXCL12 可作为疾病活动的互为生物标志物，但 CXCL13 也可用作治疗生物标志物。
